JERSEY CITY, N.J., Jan. 30, 2018 /PRNewswire/ -- TrialScope, the global leader in clinical trial transparency and
TrialScope executives will participate in three speaking sessions at the conference, designed to help sponsors navigate the complexities that accompany increasing regulatory requirements around data disclosure and transparency.
January 30 2018 Navigate FDAAA 801 Final Rule Implementation and Compliance, 2:15pm
January 31, 2018 Navigate Varying Regulatory Requirements for Plain Language Summaries, 11:30am
Evolving Beyond Compliance — Moving the Needle on Transparency and Disclosure Initiatives, 12:15pm
"Regulatory requirements around data disclosure and transparency are changing both in the U.S. and internationally," explained Wicks. "I am excited to address these issues and deliver actionable insights for attendees, as pressure for sponsors to evolve their transparency initiatives, beyond mere compliance, continues to increase."
For more information on CBI's Publication and Clinical Data Disclosure and Transparency Conference, and the full schedule of speakers, visit: http://www.cbinet.com/conference/pc18257.
To learn more about compliance and disclosure, visit TrialScope at www.TrialScope.com.
About TrialScopeTrialScope simplifies the complexities of clinical trial transparency. TrialScope's award-winning, proven solutions have been implemented successfully and rigorously tested in the most complex environments and are managing disclosures for sponsors that are responsible for over 35% of industry sponsored clinical trials posted on clinicaltrials.gov. The company's market-driven solutions and expertise enable sponsors to improve performance, mitigate compliance risk, and ultimately optimize efficiencies with clinical content lifecycle management tools, expertise and processes. TrialScope technologies are offered via a validation-ready SaaS platform hosted in a private cloud.
Contact: Alyson Kuritz, (908) 892-7149, firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/trialscope-to-sponsor-and-present-at-cbis-5th-annual-clinical-data-disclosure-and-transparency-conference-300590000.html
Subscribe to our Free Newsletters!
Exfoliative dermatitis or erythroderma is a skin condition where the skin becomes reddened and ...
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...View All